Lakewood-Amedex names David Armstrong study chair for Nu-3 Phase 2a iDFU trial

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc.

LABT

0.00
  • Lakewood-Amedex named David G. Armstrong as study chair for its Phase 2a trial of Nu-3 in infected diabetic foot ulcers.
  • Armstrong will also serve as scientific advisor for the iDFU program.
  • Armstrong is Distinguished Professor of Surgery and Neurological Surgery at USC’s Keck School of Medicine.
  • The Phase 2a proof-of-concept study tests topical Nu-3 gel at 2%, 5%, 10% to support a potential Phase 2b trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606250802PR_NEWS_USPR_____NY91640) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.